<DOC>
	<DOC>NCT02171000</DOC>
	<brief_summary>To investigate safety, pharmacokinetics and pharmacodynamics of BIBR 1048 MS following oral administration of multiple doses (150 mg b.i.d., 7 days)</brief_summary>
	<brief_title>Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dabigatran</mesh_term>
	<criteria>1. Healthy male subjects according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate and body temperature), 12lead ECG, clinical laboratory tests 1.1 No finding of clinical relevance 1.2 No evidence of a clinically relevant concomitant disease 2. Age ≥20 and Age ≤35 years 3. Body Mass Index (BMI) ≥18 and BMI &lt;25 kg/m2 (Body Mass Index) 4. Signed and dated written informed consent prior to admission to the trial in accordance with Japanese GCP (Ministry of Health, Labour and Welfare Ordinance No.28, March 27, 1997). 1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders 2. Subject was not able to use an adequate form of contraception from the time of the first dose on Day 1 up to endof study examination 3. Diseases of the central nervous system (such as epilepsy), psychiatric disorders or neurological disorders 4. History of clinically significant orthostatic hypotension, clinically significant current or past fainting spells or blackouts. 5. Chronic or relevant acute infections 6. History of allergy/hypersensitivity (including drug allergy) which was deemed relevant to the safety assessment as judged by the investigator (excluding asymptomatic seasonal rhinitis/hay fever) any bleeding disorder including prolonged or habitual bleeding other hematologic diseases cerebral bleeding (e.g. after a car accident) concussions (head trauma resulting in injuring to brain) with or without loss of consciousness 7. Intake of drugs with a long halflife (&gt; 24 hours) within at least 1 month or less than 10 halflives, whichever was shorter, of the respective drug prior to administration or during the trial 8. Use of aspirin (including overthecounter medications), antiplatelet agents like ticlopidine or dipyridamole, chronic administration of nonsteroidal antiinflammatory drugs (NSAIDs, coumadin like anticoagulants, chronic use of corticosteroids, heparin or fibrinolytic agents within 14 days prior to administration up to endofstudy examination 9. Participation in another trial with an investigational drug within 3 months prior to administration up to endofstudy examination 10. Smoker (&gt;10 cigarettes/day or inability to refrain from smoking during the trial) 11. Alcohol abuse (more than 60 g/day; confirmed by interview) 12. Drug abuse (confirmed by interview) 13. Blood donation (more than 100 mL from 3 months prior to screening and any blood donation from screening up to endofstudy examination) 14. Excessive physical activities (within 7 days prior to the first drug administration up to endofstudy examination) 15. Any laboratory value outside the reference range that was of clinical relevance 16. Known hypersensitivity to the investigational drug or its excipients 17. Subject who was judged ineligible by the investigator or the subinvestigator 18. History of any familial bleeding disorder 19. Thrombocytes &lt; 15 x 104 /μL</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>